SNSehrish Nayab

Sehrish Nayab

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sehrish Nayab has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phage Antibiotic Synergism: A Promising Approach for Tackling Emerging Challenge of Antibiotic Resistance

    by Kinza Idress, Rabia Kanwar, Sehrish Nayab, Sohaib H. Mazhar‬, Muhammad Aamir Aslam

    Rekindling attention has been directed towards phage therapy, a technique that utilizes phages to eradicate bacterial infections by targeting specific bacteria. This review delves into the interplay between bacteriophages and antibiotics, with a focus on the emerging concept of phage-antibiotic synergism (PAS). The escalating threat of antibiotic resistance and its advancing mechanisms for resistance development underscore the imperative need for alternative approaches to treat life-threatening infections. Consideration of bacteriophages that can specifically target and eliminate particular bacteria is gaining prominence for the improved treatment of infections. Moreover, the combination of both phages and antibiotics is viewed as a more efficient means of achieving treatment objectives. The observed synergistic effects in phage-antibiotic therapies showcase proficiency in antimicrobial activity, leading to a reduction in the development of microbial resistance towards antibiotics by providing an alternative way for bacterial eradication. Key findings from recent reviews emphasize the diverse mechanisms underlying phage-antibiotic synergism, including bacterial morphological changes, interference with biofilm formation, efflux pumps, increased cell wall permeability, and the potential to overcome antibiotic-resistant strains. Furthermore, this review paper elaborates on the significance of understanding the interaction between phages and antibiotics to enhance therapeutic outcomes along with an effort to shed light on the merits and demerits of this combined therapy. This comprehensive understanding can pave the way for an innovative approach to infectious disease treatment and management.

  • Open Access

    Next Generation of Modern Approaches for Phage Therapy for Treating Multidrug-Resistant Bacterial Pathogens

    by Sehrish Nayab, Rabia Kanwar, Muhammad Aamir Aslam

    Bacteriophages are viruses that attack bacterial cells, resulting in their lysis. Since the emergence of antibiotic resistance, phages have gained attention from the scientific community and are being explored for their potential use as anti-microbial agents. Since their discovery, naturally occurring wild-type phages have been used as anti-microbial agents. Though usage of antibiotics is confronted with problems, antibiotic resistance being the most pronounced, phages also have limitations, such as harboring toxin genes, not always lytic in nature, being involved in transduction, not having a broad host range, having a short life in the body due to mammalian immune response, and being attacked by bacterial anti-phage defense mechanisms. Modern approaches to phage therapy can address these problems associated with conventional phage therapy. These modern approaches include genetic phage engineering and using phage-derived enzymes, such as depolymerases and endolysins, in their wild-type form as well as in genetically engineered form. Genetic engineering has been performed on lytic, lysogenic, and filamentous phages for desired targeted results. In this review, we discuss the previous studies that have investigated these modern approaches for phage therapy against bacterial infections. Advantages and disadvantages of phage therapy are being discussed, and it is discussed how the use of modern approaches can affect different aspects of phage therapy.

  • Open Access

    Synergism of phages and antimicrobial peptides for treating multidrug resistant bacterial pathogens

    by Sehrish Nayab, Kinza Idrees, Muhammad Aamir Aslam

    The escalating threat of antibiotic resistance and its advancing mechanisms for resistance development underscore the imperative need for alternative approaches to treat life-threatening infections. Consideration of bacteriophages, as well as antimicrobial peptides (AMPs) that can specifically target and eliminate particular bacteria, is gaining prominence for the improved treatment of infections. The effectiveness of bacteriophages and AMPs has been known for a long time, and their combined use is being investigated recently. Studies have shown that the use of phages or phage-derived enzymes (endolysins) in combination with AMPs has shown promising results in combating multidrug resistant bacteria. Bacteriophages lyse bacteria by hijacking the bacterial cell’s metabolic machinery, leading to the production of phage virus inside it and finally bursting the bacteria, while AMPs act by disrupting the bacterial cell membrane or affecting intracellular targets after penetration. In this review, we discuss previous studies on the combined use of both phages or phage-derived enzymes and AMPs, demonstrating their synergistic effects for combating multidrug resistant pathogens. Their mechanisms of action, and possible mechanisms of synergy and development of bacterial resistance to these, are discussed. Approaches, including genetic engineering, for improving their efficacy have been discussed. Safety and ethical issues regarding their use in human subjects are discussed. In summary, this review emphasizes the need for further research on the combined use of AMPs and bacteriophages to tap their potential effectiveness for treating antimicrobial-resistant infections.